
By Scott Kirsner, Globe Columnist Getting that first few million dollars from investors is tough enough. But convincing them to keep funneling money into a startup that hasn’t yet hit the big time can be even harder. So I asked… Read More

Kinvey, the TechStars startup out of Boston that provides a unique backend as a service (BaaS), has closed $5 million in a new Series-A round of financing, led by Avalon Ventures with Atlas Venture following on. Kinvey previously raised a… Read More
By Steve Chapple Special to the U-T Saturday, June 23, 2012 La Jolla venture capitalist Kevin Kinsella: he’s happy, he’s not happy, he’s realistic. He’s happy because Avalon Ventures, which he founded in 1983, has just turned a $5.3 million… Read More

About an hour north of Boston, in a city by the sea, there’s a project underway to reinvent the marine industry. More specifically, the marine defense industry. Imagine a boat that moves through the water differently from any other boat… Read More
Mandy Jackson AnaptysBio is on a partnership roll: its agreement with Gilead Sciences, announcing on 1 May is its fourth new partnership in 2012 for the discovery of novel antibodies for partners. AnaptysBio, a private firm based in San Diego… Read More
SHM-XEL platform to generate novel therapeutic antibodies SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics.
By Mike “Mish” Shedlock Business Insider A close friend of mine since high school frequently writes for Foreign Affairs Magazine, the Small Wars Journal, and places like Janes’s Defence Weekly. His latest article in the Small Wars Journal highlights compelling… Read More
By Lisa LaMotta “The Pink Sheet” DAILY AnaptysBio has gained another big partner in Celgene for its antibody discovery platform; bringing Celgene further into biologics.
By Wade Rush Xconomy Current and former MIT students gathered at the Computer History Museum in Mountain View, CA, Tuesday night to hear one of San Diego’s most renowned venture investors, Avalon Ventures founder Kevin Kinsella, share insights from a long… Read More
by Rodney Brown Mass High Tech Juliet Marine Systems Inc., Portsmouth, N.H., developer of the GHOST stealth littoral defense ship, has taken in $9.67 million in the company’s first institutional funding round, according to an SEC filing.
SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company. The strategic alliance announced today with Novartis is AnaptysBio’s second collaboration… Read More
Xconomy By: Bruce V. Bigelow The sale of Amira Pharmaceuticals will likely go down as one of the standout life sciences deals of 2011—it certainly ranks as one of the biggest payouts in San Diego, where Amira was founded in 2005.
PRNewswire Syndax Pharmaceuticals, Inc., a late-stage epigenetics oncology company, announced today that members of management will present at the following upcoming fall conferences:
BusinessWire Team will advance SHM-XELTM antibody platform to build therapeutic pipeline AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Carol G. Gallagher has joined its board of directors as Executive Chair. In addition, AnaptysBio has promoted Hamza Suria… Read More
Observed Clinical Activity Suggests OTO-104 Provides Clinically Meaningful Reduction in Vertigo Frequency and Improvement in Tinnitus San Diego, CA, September 29, 2011 — Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the… Read More
Successful completion of first year milestones demonstrates applicability of SHM platform to biodefense applications SAN DIEGO–(BUSINESS WIRE)–AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that the Defense Advanced Research Projects Agency (DARPA) has extended its contract with AnaptysBio to… Read More
Boston Herald By Donna Goodison TechStars is now a more enriching experience for start-ups. The 14-week accelerator and seed-stage investment program will start offering each participating company an additional $100,000 in funding in the form of a convertible debt note.… Read More
Oncology Report Digital Network By: Susan London SAN FRANCISCO – Entinostat, a novel oral histone deacetylase inhibitor taken once weekly, may overcome resistance to hormonal therapy in breast cancer, the results of a randomized phase-II trial suggest.
San Diego Magazine By Erin Chambers Smith Where do you go after starting San Diego’s fasting growing company, then selling it for millions? If you’re 26 at the time, like Jon Carder was in 2006 when he sold online loan… Read More
Xconomy by Arlene Weintraub Just two months after reporting positive data from a clinical trial of its lead drug candidate in lung cancer, Waltham, MA-based Syndax said today that the same drug performed well in a Phase 2 breast cancer… Read More